<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ETM</journal-id>
<journal-title-group>
<journal-title>Experimental and Therapeutic Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-0981</issn>
<issn pub-type="epub">1792-1015</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">ETM-23-3-11117</article-id>
<article-id pub-id-type="doi">10.3892/etm.2022.11117</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>lncRNA Kcnq1ot1 promotes bone formation by inhibiting miR-98-5p/Tbx5 axis in MC3T3-E1 cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Furong</given-names></name>
<xref rid="af1-ETM-23-3-11117" ref-type="aff"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Fucai</given-names></name>
<xref rid="af1-ETM-23-3-11117" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zheng</surname><given-names>Feng</given-names></name>
<xref rid="af1-ETM-23-3-11117" ref-type="aff"/>
<xref rid="c1-ETM-23-3-11117" ref-type="corresp"/>
</contrib>
</contrib-group>
<aff id="af1-ETM-23-3-11117">Department of Orthopedics, Qinghai Provincial People&#x0027;s Hospital, Chengdong, Xining, Qinghai 810007, P.R. China</aff>
<author-notes>
<corresp id="c1-ETM-23-3-11117"><italic>Correspondence to:</italic> Dr Feng Zheng, Department of Orthopedics, Qinghai Provincial People&#x0027;s Hospital, 2 Gonghe Road, Chengdong, Xining, Qinghai 810007, P.R. China <email>hydgk2011@126.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>03</month>
<year>2022</year></pub-date>
<pub-date pub-type="epub">
<day>05</day>
<month>01</month>
<year>2022</year></pub-date>
<volume>23</volume>
<issue>3</issue>
<elocation-id>194</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>06</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>07</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Wang et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Long non-coding (lnc)RNA KCNQ1 opposite strand/antisense transcript 1 (Kcnq1ot1) has been shown to regulate multiple biological processes. However, the functional role of Kcnq1ot1 in osteoporosis and the underlying mechanism are still unclear. The present study aimed to investigate the function of lncRNA Kcnq1ot1 in osteogenic differentiation. Alkaline phosphatase (ALP) activity was measured using an ALP assay kit. Western blotting was performed to assess the expression levels of osteogenic differentiation-associated proteins. Reverse transcription-quantitative PCR was performed to detect Kcnq1ot1, microRNA (miR)-98-5p and T-box transcription factor 5 (Tbx5) expression levels. The binding of Kcnq1ot1 with miR-98-5p and that of miR-98-5p with Tbx5 were predicted by starBase and TargetScan databases, respectively, and verified using dual luciferase reporter assays. The mineralization of MC3T3-E1 cells was observed using an Alizarin red S staining assay. The results revealed that expression of Kcnq1ot1 was increased and that of miR-98-5p was decreased during osteogenic differentiation. Additionally, Kcnq1ot1 was shown to target miR-98-5p and inhibit its expression. Inhibiting miR-98-5p reversed the inhibitory effect of Kcnq1ot1 knockdown on osteogenic differentiation and mineralization of MC3T3-E1 cells. Furthermore, Kcnq1ot1 regulated Tbx5 expression via miR-98-5p. Overexpressing miR-98-5p or downregulating Tbx5 expression reversed the promotive effect of Kcnq1ot1 overexpression on osteogenic differentiation and mineralization of MC3T3-E1 cells. In conclusion, these findings suggested that Kcnq1ot1 may promote bone formation by inhibiting miR-98-5p and upregulating Tbx5. Kcnq1ot1, miR-98-5p and Tbx5 may therefore serve as promising targets for the treatment of osteoporosis.</p>
</abstract>
<kwd-group>
<kwd>long non-coding RNA KCNQ1 opposite strand/antisense transcript 1</kwd>
<kwd>microRNA-98-5p</kwd>
<kwd>T-box transcription factor 5</kwd>
<kwd>osteogenesis</kwd>
<kwd>bone formation</kwd>
</kwd-group>
<funding-group>
<funding-statement><bold>Funding:</bold> The present study was supported by Basic Research Project of Qinghai Provincial Science and Technology Department, China (grant no. 2020-ZJ-755).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Osteoporosis is a &#x2018;silent disease&#x2019; that results in fragile bones that are prone to fracture and lacks obvious symptoms at the beginning of the pathological process (<xref rid="b1-ETM-23-3-11117" ref-type="bibr">1</xref>). The loss of bone, decrease in bone mass, destruction of bone microstructure and increase in bone brittleness can lead to systemic bone disease in patients with osteoporosis (<xref rid="b2-ETM-23-3-11117" ref-type="bibr">2</xref>). Osteoporosis can be classified as primary or secondary according to its etiology. The etiology of primary osteoporosis is still not clear, but secondary osteoporosis is often caused by endocrine metabolic disease (such as hyperthyroidism and hyperparathyroidism) and can also be caused by certain drugs (such as glucocorticoids) that affect bone metabolism (<xref rid="b3-ETM-23-3-11117 b4-ETM-23-3-11117 b5-ETM-23-3-11117" ref-type="bibr">3-5</xref>). In general, adequate calcium intake, a healthy diet and physical activity contribute to good bone health and decrease the risk of osteoporosis (<xref rid="b6-ETM-23-3-11117 b7-ETM-23-3-11117 b8-ETM-23-3-11117" ref-type="bibr">6-8</xref>). However, age is associated with the onset of osteoporosis, which is why this disease is considerably more common in older individuals (<xref rid="b9-ETM-23-3-11117" ref-type="bibr">9</xref>). In China, the prevalence of osteoporosis in the elderly (&#x003E;60 years old) is 36&#x0025;, amongst which, the incidence is &#x007E;23&#x0025; in males and &#x007E;49&#x0025; in females (<xref rid="b10-ETM-23-3-11117" ref-type="bibr">10</xref>-<xref rid="b11-ETM-23-3-11117" ref-type="bibr">11</xref>). Fractures are a serious consequence of osteoporosis. In 2010, the number of fractures caused by osteoporosis in China reached 2.23 million, of which 1.11 million were spinal fractures and 360,000 were pelvic fractures (<xref rid="b12-ETM-23-3-11117" ref-type="bibr">12</xref>). According to various reports, osteoporosis has become one important factor affecting the quality of life of middle-aged and elderly individuals (<xref rid="b13-ETM-23-3-11117" ref-type="bibr">13</xref>,<xref rid="b14-ETM-23-3-11117" ref-type="bibr">14</xref>). Therefore, it is necessary to identify diagnostic markers and therapeutic targets for improved diagnosis and treatment of osteoporosis.</p>
<p>Long non-coding RNA (lncRNA) serves a role in cell proliferation, migration and differentiation, among numerous other processes (<xref rid="b15-ETM-23-3-11117" ref-type="bibr">15</xref>,<xref rid="b16-ETM-23-3-11117" ref-type="bibr">16</xref>). lncRNA KCNQ1 opposite strand/antisense transcript 1 (Kcnq1ot1) is an imprinted antisense lncRNA in the human KCNQ1 locus and is associated with bone formation (<xref rid="b17-ETM-23-3-11117" ref-type="bibr">17</xref>). Additionally, Kcnq1ot1 has been shown to facilitate osteogenic differentiation of human bone marrow-derived mesenchymal stem cells via the microRNA (miRNA or miR)-320a/Smad5 axis (<xref rid="b18-ETM-23-3-11117" ref-type="bibr">18</xref>). Furthermore, miR-98-5p has been reported to participate in myocardial differentiation of bone marrow mesenchymal stem cells via the regulation of T-box transcription factor 5 (Tbx5) (<xref rid="b19-ETM-23-3-11117" ref-type="bibr">19</xref>). In addition, this miRNA may target high mobility group AT-hook 2 to inhibit the osteogenic differentiation of MC3T3-E1 osteoblasts, thereby obstructing bone regeneration (<xref rid="b20-ETM-23-3-11117" ref-type="bibr">20</xref>). Thus, it was hypothesized that Kcnq1ot1 may affect osteogenic differentiation by binding to miR-98-5p. The aim of the present study was to verify this hypothesis to clarify the role of miR-98-5p in osteogenic differentiation and identify novel therapeutic targets for the treatment of osteoporosis.</p>
</sec>
<sec sec-type="Materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Bioinformatics analysis</title>
<p>starBase database (<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://starbase.sysu.edu.cn/index.php/">starbase.sysu.edu.cn/index.php/</ext-link>) was used to predict the binding site of Kcnq1ot1 and miR-98-5p. miR-98-5p and Tbx5 target site was predicted using TargetScan (<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://targetscan.org/vert_72/">targetscan.org/vert_72/</ext-link>).</p>
</sec>
<sec>
<title>Cell culture</title>
<p>The MC3T3-E1 mouse pre-osteoblast cell line was sourced from the American Type Culture Collection (cat. no. CRL-2594) and cultured in &#x03B1;-Minimum Essential Medium (cat. no. A1049001) supplemented with ribonucleosides, deoxyribonucleosides, 2 mM L-glutamine and 1 mM sodium pyruvate and 10&#x0025; FBS (all Gibco; Thermo Fisher Scientific, Inc.) in the absence of ascorbic acid. Cells were cultured at 37&#x02DA;C in a humidified incubator with 5&#x0025; CO<sub>2</sub> and the medium was replaced every 2-3 days.</p>
</sec>
<sec>
<title>Induction of osteogenic differentiation</title>
<p>Osteogenic differentiation of MC3T3-E1 cells was induced by incubation with osteogenesis-inducing medium at 80&#x0025; confluence for 14 days at 37&#x02DA;C, as previously described (<xref rid="b18-ETM-23-3-11117" ref-type="bibr">18</xref>). The medium consisted of 10&#x0025; FBS (Gibco; Thermo Fisher Scientific, Inc.), 5 mM L-glycerophosphate (Sigma-Aldrich; Merck KGaA), 100 nM dexamethasone (AmyJet Scientific, Inc.) and 50 mg/ml ascorbic acid (Shanghai Aladdin Biochemical Technology Co., Ltd.).</p>
</sec>
<sec>
<title>Cell transfection</title>
<p>Short hairpin (sh)RNA plasmid for Kcnq1ot1 (sh-Kcnq1ot1; 5&#x0027;-GCAGAACCAUCGAUGGUGCGU-3&#x0027;), shRNA targeting Tbx5 (sh-Tbx5; 5&#x0027;-CGGCUGCUAGUGUCUAUGUUU-3&#x0027;), shRNA-negative control (sh-NC; 5&#x0027;-AGUGCUGCGCACGUGUCUCAU-3&#x0027;), pcDNA3.1(+)/Kcnq1ot1 plasmid (pc-Kcnq1ot1; 5&#x0027;-GGGGTACCCCAGGTGACAAGGTGCAGGCGC-3&#x0027;), pcDNA3.1 (5&#x0027;-AUCUCCGGGGUUUACGUAUAC-3&#x0027;), miR-98-5p antagomir (antagomiR-98-5p; 5&#x0027;-AACAAUACAACUUACUACCUCA-3&#x0027;), antagomiR-NC (5&#x0027;-UCACAACCUCCUAGAAAGAGUAGA-3&#x0027;), miR-98-5p agomir (agomiR-98-5p; 5&#x0027;-UGAGGUAGUAAGUUGUAUUGUU-3&#x0027;) and agomiR-NC (5&#x0027;-UCGCUUGGUGCAGGUCGGG-3&#x0027;) were constructed by Shanghai GenePharma, Co., Ltd. A final concentration of 100 nM shRNA, pcDNA, antagomir or agomir of miR-98-5p and NC was transfected into MC3T3-E1 cells using Lipofectamine<sup>&#x00AE;</sup> 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) at 37&#x02DA;C for 48 h. At transfection, cells were harvested, and reverse transcription-quantitative PCR (RT-qPCR) was performed to assess the transfection efficiency. On the 7th day of osteogenic differentiation, transfection as aforementioned was performed to maintain the altered gene expression.</p>
</sec>
<sec>
<title>Alkaline phosphatase (ALP) activity assay</title>
<p>ALP activity was measured to assess differentiation of MC3T3-E1 cells. Briefly, cells were seeded into 12-well plates at a density of 4x10<sup>4</sup> cells/ml 37&#x02DA;C for 7 days. Subsequently, the cells were fixed in 4&#x0025; paraformaldehyde for 30 min at room temperature and treated with 0.3 nitro-blue tetrazolium and 0.15 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (Sigma-Aldrich; Merck KGaA) at room temperature for 2 h. Cells were then washed with deionized water and observed under an inverted light microscope (Nikon Corporation; magnification, x200) at a wavelength of 405 nm.</p>
</sec>
<sec>
<title>Western blotting</title>
<p>Total protein was extracted from MC3T3-E1 cells using RIPA lysis buffer (Beyotime Institute of Biotechnology). The protein concentration was determined using a BCA assay kit (Beyotime Institute of Biotechnology). A total of 30 &#x00B5;g protein/well was resolved using 10&#x0025; SDS-PAGE and transferred to a PVDF membrane. Subsequently, 5&#x0025; non-fat milk was used to block the membrane at 37&#x02DA;C for 1 h, followed by incubation at room temperature for 1 h with primary antibodies as follows: Runt-related transcription factor 2 (RUNX2; 1:1,000; cat. no. 12556; Cell Signaling Technology, Inc.), collagen type I &#x03B1; 1 (COL1A1; 1:1,000; cat. no. ab34710; Abcam), osteopontin (1:1,000, cat. no. ab214050; Abcam), osteocalcin (1:1,000, cat. no. ab133612; Abcam), Tbx5 (cat. no. ab259980; Abcam) and GAPDH (1:2,500, cat. no. ab9485; Abcam). The membrane was then incubated with horseradish peroxidase-conjugated anti-rabbit IgG secondary antibody (1:2,000, cat. no. &#x0023;5127; Cell Signaling Technology, Inc.) at room temperature for 2 h. The bands were visualized by using an enhanced chemiluminescence (ECL) reagent kit (Shanghai Yeasen Biotechnology Co., Ltd.) and semi-quantified with Image J software (Version 1.49; National Institutes of Health).</p>
</sec>
<sec>
<title>RT-qPCR</title>
<p>Total RNA was extracted from MC3T3-E1 cells using TRIzol<sup>&#x00AE;</sup> (Invitrogen; Thermo Fisher Scientific, Inc.). RT was performed to synthesize cDNA from total RNA, using a PrimeScript RT Reagent kit, according to the manufacturer&#x0027;s protocol (Takara Bio, Inc.). A SYBR green PCR Master Mix kit (cat. no. SR1110; Beijing Solarbio Science &#x0026; Technology Co., Ltd.) was used for cDNA amplification by qPCR in accordance with the manufacturer&#x0027;s instructions on an AFD9600 PCR system (Hangzhou AGS BioTech Co., Ltd.). The primer sequences for PCR were as follows: Kcnq1ot1 forward, 5&#x0027;-ACTCACTCACTCACTCACT-3&#x0027; and reverse, 5&#x0027;-CTGGCTCCTTCTATCACATT-3&#x0027;; miR-98-5p forward, 5&#x0027;-ATCCAGTGCGTGTCGTG-3&#x0027; and reverse, 5&#x0027;-TGCTTGAGGTAGTAAGTTG-3&#x0027;; Tbx5 forward, 5&#x0027;-AAGTAAAGAATATCCCGTGGTC-3&#x0027; and reverse, 5&#x0027;-AGACTCGCTGCTGAAAGG-3&#x0027;; GAPDH forward, 5&#x0027;-GGGAAACTGTGGCGTGAT-3&#x0027; and reverse, 5&#x0027;-GAGTGGGTGTCGCTGTTGA-3&#x0027; and U6 forward, 5&#x0027;-CTCGCTTCGGCAGCACATATA-3&#x0027; and reverse, 5&#x0027;-ACGCTTCACGAATTTGAGTGTC-3&#x0027;. The thermocycling conditions were as follows: 94&#x02DA;C for 60 sec, followed by 40 cycles of 94&#x02DA;C for 30 sec, 60&#x02DA;C for 30 sec and 72&#x02DA;C for 60 sec. The 2<sup>-&#x0394;&#x0394;Cq</sup> method (<xref rid="b21-ETM-23-3-11117" ref-type="bibr">21</xref>) was used to calculate relative gene expression. GAPDH was used as an internal reference for Kcnq1ot1 and Tbx5, while U6 was used as the control gene for miR-98-5p.</p>
</sec>
<sec>
<title>Dual luciferase reporter assay</title>
<p>The wild-type (Kcnq1ot1-WT or Tbx5-WT) and mutant (Kcnq1ot1-MUT or Tbx5-MUT) 3&#x0027;-untranslated regions were cloned into a pmirGLO vector (Shanghai GenePharma Co., Ltd.). For luciferase reporter analysis, MC3T3-E1 cells were co-transfected with luciferase reporter vectors, agomiR-98-5p (5&#x0027;-UGAGGUAGUAAGUUGUAUUGUU-3&#x0027;) and agomiR-NC (5&#x0027;-UCGCUUGGUGCAGGUCGGG-3&#x0027;) using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). At 48 h after transfection, the relative luciferase activities were measured by using a Dual-Luciferase Reporter Assay (Promega Corporation) and normalized to <italic>Renilla</italic> luciferase reporter activity according to the manufacturer&#x0027;s protocol.</p>
</sec>
<sec>
<title>Alizarin red S (ARS) staining assay</title>
<p>An ARS staining kit (GuideChem) was used to detect the formation of mineralized nodules in MC3T3-E1 osteoblasts. Following induction of osteogenesis and cell fixation with 95&#x0025; ethanol for 20 min at room temperature, the cells were washed with PBS (Shanghai Aladdin Biochemical Technology Co., Ltd.) three times and stained with ARS staining solution for 30 min at room temperature. The cells were observed and images were obtained using a light microscope (magnification, x200).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>All experiments were performed independently three times. GraphPad Prism version 6.0 (GraphPad Software, Inc.) was used to analyze the data. Data are presented as the mean &#x00B1; SD. One-way ANOVA followed by Tukey&#x0027;s post hoc test was used for comparisons between multiple groups. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="Results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Kcnq1ot1 expression is increased and miR-98-5p expression is decreased during osteogenic differentiation</title>
<p>A time-dependent increase in the relative activity of ALP was observed during the incubation of MC3T3-E1 osteoblasts in osteogenesis-inducing medium, indicating the occurrence of osteogenic differentiation (<xref rid="f1-ETM-23-3-11117" ref-type="fig">Fig. 1A</xref>). The protein expression levels of osteogenic differentiation-associated proteins, RUNX2, COL1A1, osteopontin and osteocalcin, were also increased in a time-dependent manner following incubation of MC3T3-E1 cells in osteogenesis-inducing medium (<xref rid="f1-ETM-23-3-11117" ref-type="fig">Fig. 1B</xref> and <xref rid="f1-ETM-23-3-11117" ref-type="fig">C</xref>). The expression of Kcnq1ot1 was elevated, and that of miR-98-5p was decreased as the duration of osteogenesis induction increased (<xref rid="f1-ETM-23-3-11117" ref-type="fig">Fig. 1D</xref>). These results suggested that Kcnq1ot1 expression increased and miR-98-5p expression decreased during osteogenic differentiation.</p>
</sec>
<sec>
<title>Kcnq1ot1 targets and inhibits miR-98-5p</title>
<p>According to starBase, Kcnq1ot1 was predicted to bind to miR-98-5p (<xref rid="f2-ETM-23-3-11117" ref-type="fig">Fig. 2A</xref>). A dual luciferase reporter assay showed decreased luciferase activity in MC3T3-E1 cells co-transfected with agomiR-98-5p and Kcnq1ot1-WT compared with that in cells co-transfected with agomiR-98-5p and Kcnq1ot1-MUT, which verified the binding between Kcnq1ot1 and miR-98-5p (<xref rid="f2-ETM-23-3-11117" ref-type="fig">Fig. 2B</xref>). Furthermore, following successful knockdown of Kcnq1ot1 (<xref rid="f2-ETM-23-3-11117" ref-type="fig">Fig. 2C</xref>), the expression of miR-98-5p was significantly upregulated compared with the control group (<xref rid="f2-ETM-23-3-11117" ref-type="fig">Fig. 2D</xref>). These results suggest that Kcnq1ot1 may target and inhibit miR-98-5p in MC3T3-E1 cells.</p>
</sec>
<sec>
<title>Antagonizing miR-98-5p reverses the inhibitory effect of Kcnq1ot1 knockdown on osteogenic differentiation</title>
<p>To determine the role of the interaction between miR-98-5p and Kcnq1ot1 in osteogenic differentiation, MC3T3-E1 cells were transfected with sh-Kcnq1ot1 or co-transfected with sh-Kcnq1ot1 and antagomiR-98-5p. The knockdown effect of antagomiR-98-5p was detected by RT-qPCR (<xref rid="f3-ETM-23-3-11117" ref-type="fig">Fig. 3A</xref>). miR-98-5p expression was increased by sh-Kcnq1ot1; this was rescued following co-transfection of sh-Kcnq1ot1 and antagomiR-98-5p (<xref rid="f3-ETM-23-3-11117" ref-type="fig">Fig. 3B</xref>). Kcnq1ot1 knockdown also decreased ALP activity, whereas inhibition of miR-98-5p restored ALP activity (<xref rid="f3-ETM-23-3-11117" ref-type="fig">Fig. 3C</xref>). Kcnq1ot1 knockdown significantly inhibited the formation of mineralized nodules, which was rescued following co-transfection of sh-Kcnq1ot1 and antagomiR-98-5p in MC3T3-E1 cells (<xref rid="f3-ETM-23-3-11117" ref-type="fig">Fig. 3D</xref>). Kcnq1ot1 knockdown also significantly inhibited the expression of RUNX2, COL1A1, osteopontin and osteocalcin, whereas antagonizing miR-98-5p in the presence of Kcnq1ot1 knockdown significantly upregulated expression of these proteins (<xref rid="f3-ETM-23-3-11117" ref-type="fig">Fig. 3E</xref>). These results indicated that antagonizing miR-98-5p may reverse the inhibitory effect of Kcnq1ot1 knockdown on osteogenic differentiation.</p>
</sec>
<sec>
<title>Kcnq1ot1 regulates Tbx5 expression via miR-98-5p</title>
<p>TargetScan software was used to predict the binding sites between Tbx5 and miR-98-5p (<xref rid="f4-ETM-23-3-11117" ref-type="fig">Fig. 4A</xref>). The transfection efficiency of pc-Kcnq1ot1 and agomiR-98-5p was detected by RT-qPCR (<xref rid="f4-ETM-23-3-11117" ref-type="fig">Fig. 4B</xref> and <xref rid="f4-ETM-23-3-11117" ref-type="fig">C</xref>). A dual luciferase reporter assay confirmed the results of the TargetScan prediction as significantly decreased relative luciferase activity was observed in MC3T3-E1 cells co-transfected with Tbx5-WT and agomiR-98-5p. Furthermore, MC3T3-E1 cells transfected with Tbx5-WT, agomiR-98-5p and pc-Kcnq1ot1 exhibited increased luciferase activity compared with the Tbx5-WT + agomiR-98-5p group (<xref rid="f4-ETM-23-3-11117" ref-type="fig">Fig. 4D</xref>). The results of RT-qPCR and western blotting both showed that Tbx5 expression was significantly downregulated by agomiR-98-5p but upregulated following Kcnq1ot1 overexpression (<xref rid="f4-ETM-23-3-11117" ref-type="fig">Fig. 4E</xref> and <xref rid="f4-ETM-23-3-11117" ref-type="fig">F</xref>). These results indicated that Kcnq1ot1 may exert a regulatory effect on Tbx5 expression via modulating miR-98-5p.</p>
</sec>
<sec>
<title>miR-98-5p overexpression and Tbx5 knockdown reverse the promotive effect of Kcnq1ot1 overexpression on osteogenic differentiation and mineralization</title>
<p>To determine the role of the interaction between miR-98-5p and Kcnq1ot1, as well as that between Tbx5 and Kcnq1ot1, in osteogenic differentiation and mineralization, agomiR-98-5p or sh-Tbx5 were transfected into MC3T3-E1 cells overexpressing Kcnq1ot1. The transfection efficiency of sh-Tbx5 was detected by RT-qPCR (<xref rid="f5-ETM-23-3-11117" ref-type="fig">Fig. 5A</xref>). Tbx5 expression was decreased in both the pc-Kcnq1ot1 + agomiR-98-5p and pc-Kcnq1ot1 + sh-Tbx5 groups (<xref rid="f5-ETM-23-3-11117" ref-type="fig">Fig. 5B</xref>). Meanwhile, the relative increase in ALP activity following Kcnq1ot1 overexpression was decreased following miR-98-5p overexpression or Tbx5 knockdown (<xref rid="f5-ETM-23-3-11117" ref-type="fig">Fig. 5C</xref>). Kcnq1ot1 overexpression significantly increased mineralization of MC3T3-E1 cells, and this was decreased following transfection with agomiR-98-5p or sh-Tbx5 (<xref rid="f5-ETM-23-3-11117" ref-type="fig">Fig. 5D</xref> and <xref rid="f5-ETM-23-3-11117" ref-type="fig">E</xref>). These results suggested that overexpressing miR-98-5p or knocking down Tbx5 may reverse the promotive effect of Kcnq1ot1 overexpression on osteogenic differentiation and mineralization.</p>
</sec>
<sec>
<title>miR-98-5p overexpression and Tbx5 knockdown reverse the promotive effect of Kcnq1ot1 overexpression on osteogenic differentiation-associated protein expression</title>
<p>The expression levels of osteogenic differentiation-associated proteins, RUNX2, COL1A1, osteopontin and osteocalcin, were detected following co-transfection of pc-Kcnq1ot1 with agomiR-98-5p or sh-Tbx5. The expression levels of differentiation-associated proteins were increased by Kcnq1ot1 knockdown and inhibited by co-transfection of pc-Kcnq1ot1 and agomiR-98-5p or pc-Kcnq1ot1 and sh-Tbx5 (<xref rid="f6-ETM-23-3-11117" ref-type="fig">Fig. 6</xref>). These findings suggested that miR-98-5p overexpression and Tbx5 knockdown may reverse the promotive effect of Kcnq1ot1 overexpression on osteogenic differentiation-associated protein expression levels.</p>
</sec>
</sec>
</sec>
<sec sec-type="Discussion">
<title>Discussion</title>
<p>Osteoporosis is a metabolic bone disease that is characterized by a severe decrease in bone density and mass (<xref rid="b22-ETM-23-3-11117" ref-type="bibr">22</xref>). Dysfunction of either osteoblasts or osteoclasts can affect bone formation and resorption, ultimately leading to metabolic bone disease (<xref rid="b22-ETM-23-3-11117" ref-type="bibr">22</xref>,<xref rid="b23-ETM-23-3-11117" ref-type="bibr">23</xref>). In osteoporosis, back pain or body aches decrease quality of life, whereas spinal deformities and fractures can be disabling, limiting mobility and the ability to function independently (<xref rid="b24-ETM-23-3-11117" ref-type="bibr">24</xref>). In addition, osteoporosis increases the risk of lung infection and bedsores when patients are bedridden for long periods of time. These not only seriously threaten quality of life and survival rate of patients, but also pose a heavy economic burden to individuals, families and society (<xref rid="b25-ETM-23-3-11117" ref-type="bibr">25</xref>).</p>
<p>The involvement of miRNAs, lncRNAs and circular RNAs in various types of disease, including osteoporosis, has been reported by an increasing number of studies (<xref rid="b26-ETM-23-3-11117 b27-ETM-23-3-11117 b28-ETM-23-3-11117" ref-type="bibr">26-28</xref>). A recent study showed that adipogenesis and osteogenesis of tendon stem cells are inhibited by Kcnq1ot1 knockdown, which exerts its effect via indirect inhibition of the miR-138 target genes peroxisome proliferator activator receptor &#x03B3; and RUNX2(<xref rid="b29-ETM-23-3-11117" ref-type="bibr">29</xref>). Kcnq1ot1 has also been shown to positively regulate osteogenic differentiation of bone marrow mesenchymal stem cells by sponging miR-214(<xref rid="b30-ETM-23-3-11117" ref-type="bibr">30</xref>). The proliferative capacity of human osteoblastic cell line is less than that of mouse MC3T3-E1 cells, so human cell lines were not suitable for the present study. In addition, induction of osteogenic differentiation in human cells is harder than in mouse cell lines (<xref rid="b31-ETM-23-3-11117" ref-type="bibr">31</xref>). Human and mouse genes are highly homologous, thus MC3T3-E1 cell line was investigated in the present study rather than human osteoblastic cells (<xref rid="b32-ETM-23-3-11117" ref-type="bibr">32</xref>). In the present study, increased expression of Kcnq1ot1 was observed in MC3T3-E1 cells. Kcnq1ot1 silencing significantly inhibited osteogenic differentiation and mineralization in MC3T3-E1 cells, which was consistent with a previous report (<xref rid="b33-ETM-23-3-11117" ref-type="bibr">33</xref>). According to starBase, Kcnq1ot1 shares binding sites with miR-98-5p. A dual luciferase reporter assay was then performed, which verified the binding between Kcnq1ot1 and miR-98-5p. Furthermore, the expression of miR-98-5p was significantly upregulated in MC3T3-E1 cells following Kcnq1ot1 knockdown. miR-98-5p overexpression inhibits osteogenic differentiation and proliferation of MC3T3-E1 osteoblasts by targeting high mobility group AT-Hook2, thereby obstructing bone regeneration (<xref rid="b20-ETM-23-3-11117" ref-type="bibr">20</xref>). In agreement with the aforementioned studies, miR-98-5p silencing rescued the inhibitory effect of Kcnq1ot1 knockdown on osteogenic differentiation and mineralization, suggesting that Kcnq1ot1 silencing may serve a suppressive role in bone formation by upregulating miR-98-5p expression.</p>
<p>The present study investigated the interaction between Kcnq1ot1 and miR-98-5p and the mechanism of miR-98-5p in osteogenic differentiation. According to a previous study, miR-98-5p targets the transcription factor Tbx5 and obstructs the transition of rat mesenchymal stem cells into cardiomyocytes (<xref rid="b19-ETM-23-3-11117" ref-type="bibr">19</xref>). Furthermore, TargetScan predicted binding of miR-98-5p to Tbx5. Tbx5 has been reported to promote the differentiation of 5-azacytidine-treated cardiac fibroblasts into cardiomyocytes (<xref rid="b34-ETM-23-3-11117" ref-type="bibr">34</xref>). Another study showed that miR-10-5p impedes myocardial differentiation of bone marrow mesenchymal stem cells via inhibition of Tbx5(<xref rid="b35-ETM-23-3-11117" ref-type="bibr">35</xref>). Therefore, it was hypothesized that Kcnq1ot1 may target miR-98-5p and upregulate expression of Tbx5, thereby promoting differentiation. In the present study, the dual luciferase reporter assay confirmed the binding between miR-98-5p and Tbx5. The data revealed that knockdown of miR-98-5p significantly decreased Tbx5 expression, which was rescued by Kcnq1ot1 overexpression. This suggested that Kcnq1ot1 regulated Tbx5 expression via miR-98-5p. In addition, less osteogenic differentiation and mineralization, as well as decreased expression levels of RUNX2, COL1A1, osteopontin and osteocalcin in MC3T3-E1 cells, were observed following Kcnq1ot1 overexpression or transfection with agomiR-98-5p or sh-Tbx5. These results suggested that miR-98-5p overexpression or Tbx5 knockdown may reverse the promotive effect of Kcnq1ot1 overexpression on the osteogenic differentiation of MC3T3-E1 cells. The present results also revealed that the increase in Tbx5 expression levels induced by Kcnq1ot1 overexpression was significantly suppressed by sh-Tbx5. However, the suppressive effect of agomiR-98-5p on the increased Tbx5 level was marginal. It was hypothesized that other unidentified specific pathways regulate the Kcnq1ot1/miR-98-5p/Tbx5 axis. This should be confirmed <italic>in vivo</italic> and in clinical practice. The MC3T3-E1 cell line is a classical and common cell model used to study osteogenic differentiation. Thus, MC3T3-E1 was selected as a representative to investigate the role of Kcnq1ot1 in bone formation and the underlying mechanism (<xref rid="b36-ETM-23-3-11117" ref-type="bibr">36</xref>,<xref rid="b37-ETM-23-3-11117" ref-type="bibr">37</xref>). Human osteoblast cell lines should be used to verify the results. Utilization of multiple cell lines may better reveal the mechanism underlying the effect of Kcnq1ot1 on osteogenic differentiation. However, the present study focused on the target and mechanism by which osteogenic differentiation regulates osteoporosis in the present study. Another limitation of the study was that the expression of Kcnq1ot1 and miR-98-5p was not assessed at early timepoints (such as day 1-3). The biological effects of Kcnq1ot1/miR-98-5p in other pre-osteoblast cell lines and other potential mechanisms should be investigated in future.</p>
<p>In conclusion, the present study showed that Kcnq1ot1 serves a role in regulating osteogenic differentiation and mineralization of MC3T3-E1 by modulating expression of miR-98-5p/Tbx5. Kcnq1ot1 may be a potential effective therapeutic molecular biomarker for treatment of osteoporosis to improve patient quality of life.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>All data generated or analyzed during this study are included in this published article.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>FW and FZhe designed the experiments and wrote the manuscript. FW, FZha and FZhe performed the experiments and analyzed the data. FZhe revised the manuscript and supervised the experiments. FW and FZha confirm the authenticity of all the raw data. All authors have read and approved the final version of the manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-ETM-23-3-11117"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlan</surname><given-names>T</given-names></name><name><surname>Dockery</surname><given-names>F</given-names></name></person-group><article-title>Osteoporosis and fracture risk in older people</article-title><source>Clin Med (Lond)</source><volume>14</volume><fpage>187</fpage><lpage>191</lpage><year>2014</year><pub-id pub-id-type="pmid">24715132</pub-id><pub-id pub-id-type="doi">10.7861/clinmedicine.14-2-187</pub-id></element-citation></ref>
<ref id="b2-ETM-23-3-11117"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamichhane</surname><given-names>AP</given-names></name></person-group><article-title>Osteoporosis-an update</article-title><source>JNMA J Nepal Med Assoc</source><volume>44</volume><fpage>60</fpage><lpage>66</lpage><year>2005</year><pub-id pub-id-type="pmid">16568580</pub-id></element-citation></ref>
<ref id="b3-ETM-23-3-11117"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compston</surname><given-names>J</given-names></name></person-group><article-title>Glucocorticoid-induced osteoporosis: An update</article-title><source>Endocrine</source><volume>61</volume><fpage>7</fpage><lpage>16</lpage><year>2018</year><pub-id pub-id-type="pmid">29691807</pub-id><pub-id pub-id-type="doi">10.1007/s12020-018-1588-2</pub-id></element-citation></ref>
<ref id="b4-ETM-23-3-11117"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>NE</given-names></name></person-group><article-title>Glucocorticoid-induced osteoporosis: New insights into the pathophysiology and treatments</article-title><source>Curr Osteoporos Rep</source><volume>17</volume><fpage>1</fpage><lpage>7</lpage><year>2019</year><pub-id pub-id-type="pmid">30685820</pub-id><pub-id pub-id-type="doi">10.1007/s11914-019-00498-x</pub-id></element-citation></ref>
<ref id="b5-ETM-23-3-11117"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>E</given-names></name><name><surname>Shane</surname><given-names>E</given-names></name></person-group><article-title>Secondary osteoporosis</article-title><source>Endocrinol Metab Clin North Am</source><volume>32</volume><fpage>115</fpage><lpage>134</lpage><year>2003</year><pub-id pub-id-type="pmid">12699295</pub-id><pub-id pub-id-type="doi">10.1016/s0889-8529(02)00062-2</pub-id></element-citation></ref>
<ref id="b6-ETM-23-3-11117"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gass</surname><given-names>M</given-names></name><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name></person-group><article-title>Preventing osteoporosis-related fractures: An overview</article-title><source>Am J Med</source><volume>119 (Suppl 1)</volume><fpage>S3</fpage><lpage>S11</lpage><year>2006</year><pub-id pub-id-type="pmid">16563939</pub-id><pub-id pub-id-type="doi">10.1016/j.amjmed.2005.12.017</pub-id></element-citation></ref>
<ref id="b7-ETM-23-3-11117"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delaney</surname><given-names>MF</given-names></name></person-group><article-title>Strategies for the prevention and treatment of osteoporosis during early postmenopause</article-title><source>Am J Obstet Gynecol</source><volume>194 (2 Suppl)</volume><fpage>S12</fpage><lpage>S23</lpage><year>2006</year><pub-id pub-id-type="pmid">16448872</pub-id><pub-id pub-id-type="doi">10.1016/j.ajog.2005.08.049</pub-id></element-citation></ref>
<ref id="b8-ETM-23-3-11117"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmona</surname><given-names>RJ</given-names></name><name><surname>Adachi</surname><given-names>JD</given-names></name></person-group><article-title>Calcium and vitamin D for osteoporotic fracture prevention</article-title><source>Pol Arch Med Wewn</source><volume>117</volume><fpage>441</fpage><lpage>442</lpage><year>2007</year><pub-id pub-id-type="pmid">18320782</pub-id></element-citation></ref>
<ref id="b9-ETM-23-3-11117"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aspray</surname><given-names>TJ</given-names></name><name><surname>Hill</surname><given-names>TR</given-names></name></person-group><article-title>Osteoporosis and the ageing skeleton</article-title><source>Subcell Biochem</source><volume>91</volume><fpage>453</fpage><lpage>476</lpage><year>2019</year><pub-id pub-id-type="pmid">30888662</pub-id><pub-id pub-id-type="doi">10.1007/978-981-13-3681-2_16</pub-id></element-citation></ref>
<ref id="b10-ETM-23-3-11117"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Hyman</surname><given-names>ME</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Osteoporosis in china</article-title><source>Osteoporos Int</source><volume>20</volume><fpage>1651</fpage><lpage>1662</lpage><year>2009</year><pub-id pub-id-type="pmid">19415374</pub-id><pub-id pub-id-type="doi">10.1007/s00198-009-0925-y</pub-id></element-citation></ref>
<ref id="b11-ETM-23-3-11117"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name></person-group><article-title>Prevalence of osteoporosis in China: A meta-analysis and systematic review</article-title><source>BMC Public Health</source><volume>16</volume><issue>1039</issue><year>2016</year><pub-id pub-id-type="pmid">27716144</pub-id><pub-id pub-id-type="doi">10.1186/s12889-016-3712-7</pub-id></element-citation></ref>
<ref id="b12-ETM-23-3-11117"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>The prevalence of osteoporosis in China, a nationwide, multicenter DXA survey</article-title><source>J Bone Miner Res</source><volume>34</volume><fpage>1789</fpage><lpage>1797</lpage><year>2019</year><pub-id pub-id-type="pmid">31067339</pub-id><pub-id pub-id-type="doi">10.1002/jbmr.3757</pub-id></element-citation></ref>
<ref id="b13-ETM-23-3-11117"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoback</surname><given-names>D</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Black</surname><given-names>DM</given-names></name><name><surname>Cheung</surname><given-names>AM</given-names></name><name><surname>Murad</surname><given-names>MH</given-names></name><name><surname>Eastell</surname><given-names>R</given-names></name></person-group><article-title>Pharmacological management of osteoporosis in postmenopausal women: An endocrine society guideline update</article-title><source>J Clin Endocrinol Metab</source><volume>105</volume><issue>dgaa048</issue><year>2020</year><pub-id pub-id-type="pmid">32068863</pub-id><pub-id pub-id-type="doi">10.1210/clinem/dgaa048</pub-id></element-citation></ref>
<ref id="b14-ETM-23-3-11117"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>CB</given-names></name><name><surname>Dagar</surname><given-names>M</given-names></name></person-group><article-title>Osteoporosis in older adults</article-title><source>Med Clin North Am</source><volume>104</volume><fpage>873</fpage><lpage>884</lpage><year>2020</year><pub-id pub-id-type="pmid">32773051</pub-id><pub-id pub-id-type="doi">10.1016/j.mcna.2020.06.004</pub-id></element-citation></ref>
<ref id="b15-ETM-23-3-11117"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>GY</given-names></name></person-group><article-title>Novel human lncRNA-disease association inference based on lncRNA expression profiles</article-title><source>Bioinformatics</source><volume>29</volume><fpage>2617</fpage><lpage>2624</lpage><year>2013</year><pub-id pub-id-type="pmid">24002109</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btt426</pub-id></element-citation></ref>
<ref id="b16-ETM-23-3-11117"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khorkova</surname><given-names>O</given-names></name><name><surname>Hsiao</surname><given-names>J</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group><article-title>Basic biology and therapeutic implications of lncRNA</article-title><source>Adv Drug Deliv Rev</source><volume>87</volume><fpage>15</fpage><lpage>24</lpage><year>2015</year><pub-id pub-id-type="pmid">26024979</pub-id><pub-id pub-id-type="doi">10.1016/j.addr.2015.05.012</pub-id></element-citation></ref>
<ref id="b17-ETM-23-3-11117"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SZ</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name></person-group><article-title>LncRNA-KCNQ1OT1: A potential target in exosomes derived From ADSCs for the treatment of osteoporosis</article-title><source>Stem Cells Int</source><volume>19</volume><issue>7690006</issue><year>2021</year><pub-id pub-id-type="pmid">34712334</pub-id><pub-id pub-id-type="doi">10.1155/2021/7690006</pub-id></element-citation></ref>
<ref id="b18-ETM-23-3-11117"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JL</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>AG</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>XJ</given-names></name></person-group><article-title>Kcnq1ot1 regulates osteogenic differentiation of hBMSC by miR-320a/Smad5 axis</article-title><source>Eur Rev Med Pharmacol Sci</source><volume>24</volume><fpage>2843</fpage><lpage>2854</lpage><year>2020</year><pub-id pub-id-type="pmid">32271402</pub-id><pub-id pub-id-type="doi">10.26355/eurrev_202003_20648</pub-id></element-citation></ref>
<ref id="b19-ETM-23-3-11117"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>HH</given-names></name><name><surname>Sun</surname><given-names>PF</given-names></name><name><surname>Liu</surname><given-names>WY</given-names></name></person-group><article-title>MiR-98-5p regulates myocardial differentiation of mesenchymal stem cells by targeting Tbx5</article-title><source>Eur Rev Med Pharmacol Sci</source><volume>22</volume><fpage>7841</fpage><lpage>7848</lpage><year>2018</year><pub-id pub-id-type="pmid">30536329</pub-id><pub-id pub-id-type="doi">10.26355/eurrev_201811_16409</pub-id></element-citation></ref>
<ref id="b20-ETM-23-3-11117"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name></person-group><article-title>MicroRNA-98-5p prevents bone regeneration by targeting high mobility group AT-Hook 2</article-title><source>Exp Ther Med</source><volume>18</volume><fpage>2660</fpage><lpage>2666</lpage><year>2019</year><pub-id pub-id-type="pmid">31555368</pub-id><pub-id pub-id-type="doi">10.3892/etm.2019.7835</pub-id></element-citation></ref>
<ref id="b21-ETM-23-3-11117"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GL</given-names></name><name><surname>Xia</surname><given-names>XL</given-names></name><name><surname>Li</surname><given-names>XL</given-names></name><name><surname>He</surname><given-names>FH</given-names></name><name><surname>Li</surname><given-names>JL</given-names></name></person-group><article-title>Identification and expression analysis of the MSP130-related-2 gene from Hyriopsis cumingii</article-title><source>Genet Mol Res</source><volume>14</volume><fpage>4903</fpage><lpage>4913</lpage><year>2015</year><pub-id pub-id-type="pmid">25966265</pub-id><pub-id pub-id-type="doi">10.4238/2015.May.11.23</pub-id></element-citation></ref>
<ref id="b22-ETM-23-3-11117"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Duan</surname><given-names>N</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Schwarz</surname><given-names>EM</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name></person-group><article-title>Osteoblast-osteoclast interactions</article-title><source>Connect Tissue Res</source><volume>59</volume><fpage>99</fpage><lpage>107</lpage><year>2018</year><pub-id pub-id-type="pmid">28324674</pub-id><pub-id pub-id-type="doi">10.1080/03008207.2017.1290085</pub-id></element-citation></ref>
<ref id="b23-ETM-23-3-11117"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazess</surname><given-names>RB</given-names></name></person-group><article-title>Fracture risk: A role for compact bone</article-title><source>Calcif Tissue Int</source><volume>47</volume><fpage>191</fpage><lpage>193</lpage><year>1990</year><pub-id pub-id-type="pmid">2242490</pub-id><pub-id pub-id-type="doi">10.1007/BF02555918</pub-id></element-citation></ref>
<ref id="b24-ETM-23-3-11117"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>PD</given-names></name></person-group><article-title>Management of severe osteoporosis</article-title><source>Expert Opin Pharmacother</source><volume>17</volume><fpage>473</fpage><lpage>488</lpage><year>2016</year><pub-id pub-id-type="pmid">26605922</pub-id><pub-id pub-id-type="doi">10.1517/14656566.2016.1124856</pub-id></element-citation></ref>
<ref id="b25-ETM-23-3-11117"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Deal</surname><given-names>C</given-names></name></person-group><article-title>Osteoporosis in elderly: Prevention and treatment</article-title><source>Clin Geriatr Med</source><volume>18</volume><fpage>529</fpage><lpage>555</lpage><year>2002</year><pub-id pub-id-type="pmid">12424871</pub-id><pub-id pub-id-type="doi">10.1016/s0749-0690(02)00022-8</pub-id></element-citation></ref>
<ref id="b26-ETM-23-3-11117"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yujiao</surname><given-names>W</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Linhui</surname><given-names>Y</given-names></name><name><surname>Ziqi</surname><given-names>G</given-names></name><name><surname>Zhichen</surname><given-names>W</given-names></name><name><surname>Zirui</surname><given-names>W</given-names></name><name><surname>Shengwang</surname><given-names>W</given-names></name></person-group><article-title>The roles of miRNA, lncRNA and circRNA in the development of osteoporosis</article-title><source>Biol Res</source><volume>53</volume><issue>40</issue><year>2020</year><pub-id pub-id-type="pmid">32938500</pub-id><pub-id pub-id-type="doi">10.1186/s40659-020-00309-z</pub-id></element-citation></ref>
<ref id="b27-ETM-23-3-11117"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Systematic analysis of lncRNAs, mRNAs, circRNAs and miRNAs in patients with postmenopausal osteoporosis</article-title><source>Am J Transl Res</source><volume>10</volume><fpage>1498</fpage><lpage>1510</lpage><year>2018</year><pub-id pub-id-type="pmid">29887963</pub-id></element-citation></ref>
<ref id="b28-ETM-23-3-11117"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>The roles of long non-coding RNA in osteoporosis</article-title><source>Curr Stem Cell Res Ther</source><volume>15</volume><fpage>639</fpage><lpage>645</lpage><year>2020</year><pub-id pub-id-type="pmid">32357819</pub-id><pub-id pub-id-type="doi">10.2174/1574888X15666200501235735</pub-id></element-citation></ref>
<ref id="b29-ETM-23-3-11117"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name></person-group><article-title>Knockdown of lncRNA Kcnq1ot1 suppresses the adipogenic and osteogenic differentiation of tendon stem cell via downregulating miR-138 target genes PPARgamma and RUNX2</article-title><source>Cell Cycle</source><volume>17</volume><fpage>2374</fpage><lpage>2385</lpage><year>2018</year><pub-id pub-id-type="pmid">30321077</pub-id><pub-id pub-id-type="doi">10.1080/15384101.2018.1534510</pub-id></element-citation></ref>
<ref id="b30-ETM-23-3-11117"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CG</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>YH</given-names></name><name><surname>Liao</surname><given-names>QD</given-names></name><name><surname>Zhong</surname><given-names>D</given-names></name></person-group><article-title>LncRNA Kcnq1ot1 promoted BMP2 expression to regulate osteogenic differentiation by sponging miRNA-214</article-title><source>Exp Mol Pathol</source><volume>107</volume><fpage>77</fpage><lpage>84</lpage><year>2019</year><pub-id pub-id-type="pmid">30703347</pub-id><pub-id pub-id-type="doi">10.1016/j.yexmp.2019.01.012</pub-id></element-citation></ref>
<ref id="b31-ETM-23-3-11117"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czekanska</surname><given-names>EM</given-names></name><name><surname>Stoddart</surname><given-names>MJ</given-names></name><name><surname>Richards</surname><given-names>RG</given-names></name><name><surname>Hayes</surname><given-names>JS</given-names></name></person-group><article-title>In search of an osteoblast cell model for in vitro research</article-title><source>Eur Cell Mater</source><volume>24</volume><fpage>1</fpage><lpage>17</lpage><year>2012</year><pub-id pub-id-type="pmid">22777949</pub-id><pub-id pub-id-type="doi">10.22203/ecm.v024a01</pub-id></element-citation></ref>
<ref id="b32-ETM-23-3-11117"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>SS</given-names></name><name><surname>Dessimoz</surname><given-names>C</given-names></name><name><surname>Bleuler</surname><given-names>S</given-names></name><name><surname>Laule</surname><given-names>O</given-names></name><name><surname>Hruz</surname><given-names>T</given-names></name><name><surname>Gruissem</surname><given-names>W</given-names></name><name><surname>Zimmermann</surname><given-names>P</given-names></name></person-group><article-title>Global regulatory architecture of human, mouse and rat tissue transcriptomes</article-title><source>BMC Genomics</source><volume>14</volume><issue>716</issue><year>2013</year><pub-id pub-id-type="pmid">24138449</pub-id><pub-id pub-id-type="doi">10.1186/1471-2164-14-716</pub-id></element-citation></ref>
<ref id="b33-ETM-23-3-11117"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>LncRNA Kcnq1ot1 promotes osteogenic differentiation to relieve osteolysis via wnt/beta-catenin activation</article-title><source>Cell Biosci</source><volume>8</volume><issue>19</issue><year>2018</year><pub-id pub-id-type="pmid">29541443</pub-id><pub-id pub-id-type="doi">10.1186/s13578-018-0216-4</pub-id></element-citation></ref>
<ref id="b34-ETM-23-3-11117"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>Transcription factor Tbx5 promotes cardiomyogenic differentiation of cardiac fibroblasts treated with 5-azacytidine</article-title><source>J Cell Biochem</source><volume>120</volume><fpage>16503</fpage><lpage>16515</lpage><year>2019</year><pub-id pub-id-type="pmid">31265161</pub-id><pub-id pub-id-type="doi">10.1002/jcb.28885</pub-id></element-citation></ref>
<ref id="b35-ETM-23-3-11117"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group><article-title>MicroRNA-10-5p regulates differentiation of bone marrow mesenchymal stem cells into cardiomyocytes by targeting Tbx5</article-title><source>Eur Rev Med Pharmacol Sci</source><volume>23</volume><fpage>479</fpage><lpage>485</lpage><year>2019</year><pub-id pub-id-type="pmid">30720154</pub-id><pub-id pub-id-type="doi">10.26355/eurrev_201901_16859</pub-id></element-citation></ref>
<ref id="b36-ETM-23-3-11117"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>Q</given-names></name></person-group><article-title>Vitamin K2 stimulates MC3T3-E1 osteoblast differentiation and mineralization through autophagy induction</article-title><source>Mol Med Rep</source><volume>19</volume><fpage>3676</fpage><lpage>3684</lpage><year>2019</year><pub-id pub-id-type="pmid">30896842</pub-id><pub-id pub-id-type="doi">10.3892/mmr.2019.10040</pub-id></element-citation></ref>
<ref id="b37-ETM-23-3-11117"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>Effect of ANGPTL7 on proliferation and differentiation of MC3T3-E1 cells</article-title><source>Med Sci Monit</source><volume>25</volume><fpage>9524</fpage><lpage>9530</lpage><year>2019</year><pub-id pub-id-type="pmid">31835268</pub-id><pub-id pub-id-type="doi">10.12659/MSM.918333</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ETM-23-3-11117" position="float">
<label>Figure 1</label>
<caption><p>Increased Kcnq1ot1 expression and decreased miR-98-5p in osteogenic differentiation. (A) Relative ALP activity detected by ALP assay kit. (B) Western blotting was performed to determine (-C) protein expression of osteogenic differentiation-associated RUNX, COL1A1, osteopontin and osteocalcin detected by western blotting. (D) mRNA expression of Kcnq1ot1 and miR-98-5p detected by reverse transcription-quantitative PCR in MC3T3-E1 cells cultured in osteogenesis-inducing medium. Data are expressed as mean &#x00B1; SD. <sup>&#x002A;&#x002A;</sup>P&#x003C;0.01, <sup>&#x002A;&#x002A;&#x002A;</sup>P&#x003C;0.001 vs. 0. Kcnq1ot1, long non-coding RNA KCNQ1 opposite strand/antisense transcript 1; miR, microRNA; ALP, alkaline phosphatase; RUNX, Runt-related transcription factor 2; COL1A1, collagen type I &#x03B1; 1.</p></caption>
<graphic xlink:href="etm-23-03-11117-g00.tif" />
</fig>
<fig id="f2-ETM-23-3-11117" position="float">
<label>Figure 2</label>
<caption><p>Kcnq1ot1 targets and inhibits miR-98-5p. (A) StarBase prediction of the shared binding sites between Kcnq1ot1 and miR-98-5p. (B) Relative luciferase activity in MC3T3-E1 cells transfected with control, Kcnq1ot1-WT + agomiR-NC or agomiR-98-5p, Kcnq1ot1-MUT + agomiR-NC or agomiR-98-5p, detected by dual-luciferase reporter assay. Relative mRNA expression of (C) Kcnq1ot1 and (D) miR-98-5p in MC3T3-E1 cells transfected with control, sh-NC or sh-Kcnq1ot1, detected by RT-qPCR. Data are expressed as mean &#x00B1; SD. <sup>&#x002A;&#x002A;&#x002A;</sup>P&#x003C;0.001 vs. control; <sup>&#x0023;&#x0023;&#x0023;</sup>P&#x003C;0.001 vs. sh-NC. Kcnq1ot1, long non-coding RNA KCNQ1 opposite strand/antisense transcript 1; miR, microRNA; WT, wild-type; NC, negative control; MUT, mutant; sh, short hairpin.</p></caption>
<graphic xlink:href="etm-23-03-11117-g01.tif" />
</fig>
<fig id="f3-ETM-23-3-11117" position="float">
<label>Figure 3</label>
<caption><p>Antagonizing miR-98-5p reverses the inhibitory effect of Kcnq1ot1 knockdown on osteogenic differentiation. (A) Relative mRNA expression of miR-98-5p in MC3T3-E1 cells was detected by reverse transcription-quantitative PCR following transfection with (A) antagomiR-98-5p or (B) control, sh-NC, sh-Kcnq1ot1, sh-Kcnq1ot1 + antagomiR-NC or sh-Kcnq1ot1 + antagomiR-98-5p. (C) Relative ALP activity in MC3T3-E1 cells transfected with control, sh-NC, sh-Kcnq1ot1, sh-Kcnq1ot1 + antagomiR-NC or sh-Kcnq1ot1 + antagomiR-98-5p detected by ALP assay kit. (D) Formation of mineralized nodules in MC3T3-E1 cells transfected with control, sh-NC, sh-Kcnq1ot1, sh-Kcnq1ot1 + antagomiR-NC or sh-Kcnq1ot1 + antagomiR-98-5p, detected by alizarin red S staining assay. Scale bar, 50 &#x00B5;m. (E) Relative protein expression of osteogenic differentiation-associated RUNX, COL1A1, osteopontin and osteocalcin in MC3T3-E1 cells transfected with control, sh-NC, sh-Kcnq1ot1, sh-Kcnq1ot1 + antagomiR-NC or sh-Kcnq1ot1 + antagomiR-98-5p detected by western blotting. Data are expressed as mean &#x00B1; SD. <sup>&#x002A;&#x002A;&#x002A;</sup>P&#x003C;0.001 vs. control; <sup>&#x0023;&#x0023;&#x0023;</sup>P&#x003C;0.001 vs. antagomiR-NC or sh-NC; <sup>&#x0026;&#x0026;</sup>P&#x003C;0.01, <sup>&#x0026;&#x0026;&#x0026;</sup>P&#x003C;0.001 vs. sh-Kcnq1ot1 + antagomiR-NC. Kcnq1ot1, long non-coding RNA KCNQ1 opposite strand/antisense transcript 1; miR, microRNA; ALP, alkaline phosphatase; RUNX, Runt-related transcription factor 2; COL1A1, collagen type I &#x03B1; 1; sh, short hairpin; NC, negative control; OD, optical density.</p></caption>
<graphic xlink:href="etm-23-03-11117-g02.tif" />
</fig>
<fig id="f4-ETM-23-3-11117" position="float">
<label>Figure 4</label>
<caption><p>Kcnq1ot1 regulates Tbx5 expression via miR-98-5p. (A) TargetScan prediction of the shared binding sites between miR-98-5p and Tbx5. Expression of (B) Kcnq1ot1 and (C) miR-98-5p was measured by RT-qPCR following transfection with pc-Kcnq1ot1 and agomiR-98-5p. (D) Relative luciferase activity in MC3T3-E1 cells transfected with control, Tbx5-WT + agomiR-NC, Tbx5-WT + agomiR-98-5p, Tbx5-WT + agomiR-98-5p + pcDNA3.1, Tbx5-WT + agomiR-98-5p + pc-Kcnq1ot1, Tbx5-MUT + agomiR-NC, Tbx5-MUT + agomiR-98-5p, Tbx5-MUT + agomiR-98-5p + pcDNA3.1, Tbx5-MUT + agomiR-98-5p + pc-Kcnq1ot1 detected by dual-luciferase reporter assay. Relative expression of Tbx5 in MC3T3-E1 cells transfected with control, agomiR-NC, agomiR-98-5p, agomiR-98-5p + pcDNA3.1 or agomiR-98-5p + pc-Kcnq1ot1, detected by (E) RT-qPCR and (F) western blot analysis. Data are expressed as mean &#x00B1; SD. <sup>&#x002A;&#x002A;&#x002A;</sup>P&#x003C;0.001 vs. control; <sup>&#x0023;&#x0023;&#x0023;</sup>P&#x003C;0.001 vs. pcDNA3.1 or agomiR-NC; <sup>&#x0026;</sup>P&#x003C;0.05, <sup>&#x0026;&#x0026;&#x0026;</sup>P&#x003C;0.001 vs. agomiR-98-5p + pcDNA3.1. Kcnq1ot1, long non-coding RNA KCNQ1 opposite strand/antisense transcript 1; miR, microRNA; sh, short hairpin; NC, negative control; Tbx5, T-box transcription factor 5; RT-q, reverse transcription-quantitative; WT, wild-type; MUT, mutant.</p></caption>
<graphic xlink:href="etm-23-03-11117-g03.tif" />
</fig>
<fig id="f5-ETM-23-3-11117" position="float">
<label>Figure 5</label>
<caption><p>miR-98-5p overexpression and Tbx5 knockdown reverse the promotive effect of Kcnq1ot1 overexpression on osteogenic differentiation and mineralization. (A) Relative mRNA expression of Tbx5 in MC3T3-E1 cells was detected by reverse transcription-quantitative PCR following transfection with sh-Tbx5. (B) Relative protein expression of Tbx5 in MC3T3-E1 cells transfected with control, pcDNA3.1, pc-Kcnq1ot1, pc-Kcnq1ot1 + agomiR-NC, pc-Kcnq1ot1 + agomiR-98-5p, pc-Kcnq1ot1 + sh-NC or pc-Kcnq1ot1 + sh-Tbx5 detected by western blotting. (C) Relative ALP activity in MC3T3-E1 cells transfected with control, pcDNA3.1, pc-Kcnq1ot1, pc-Kcnq1ot1 + agomiR-NC, pc-Kcnq1ot1 + agomiR-98-5p, pc-Kcnq1ot1 + sh-NC or pc-Kcnq1ot1 + sh-Tbx5 detected by ALP assay kit. (D) Formation of mineralized nodules in MC3T3-E1 cells transfected with control, pcDNA3.1, pc-Kcnq1ot1, pc-Kcnq1ot1 + agomiR-NC, pc-Kcnq1ot1 + agomiR-98-5p, pc-Kcnq1ot1 + sh-NC or pc-Kcnq1ot1 + sh-Tbx5 (E) detected by alizarin red S staining assay. Scale bar, 50 &#x00B5;m. Data are expressed as mean &#x00B1; SD. <sup>&#x002A;&#x002A;&#x002A;</sup>P&#x003C;0.001 vs. pcDNA3.1; <sup>&#x0023;</sup>P&#x003C;0.05, <sup>&#x0023;&#x0023;&#x0023;</sup>P&#x003C;0.001 vs. sh-NC or pc-Kcnq1ot1 + agomiR-NC; <sup>&#x0026;&#x0026;&#x0026;</sup>P&#x003C;0.001 vs. pc-Kcnq1ot1 + sh-NC. Kcnq1ot1, long non-coding RNA KCNQ1 opposite strand/antisense transcript 1; miR, microRNA; sh, short hairpin; NC, negative control; Tbx5, T-box transcription factor 5; ALP, alkaline phosphatase; OD, optical density.</p></caption>
<graphic xlink:href="etm-23-03-11117-g04.tif" />
</fig>
<fig id="f6-ETM-23-3-11117" position="float">
<label>Figure 6</label>
<caption><p>miR-98-5p overexpression and Tbx5 knockdown reverse the promotive effect of Kcnq1ot1 overexpression on osteogenic differentiation-associated protein expression. Relative protein expression of osteogenic differentiation-associated RUNX2, COL1A1, osteopontin and osteocalcin in MC3T3-E1 cells transfected with control, pcDNA3.1, pc-Kcnq1ot1, pc-Kcnq1ot1 + agomiR-NC, pc-Kcnq1ot1 + agomiR-98-5p, pc-Kcnq1ot1 + sh-NC or pc-Kcnq1ot1 + sh-Tbx5 detected by western blotting. Data are expressed as mean &#x00B1; SD. <sup>&#x002A;&#x002A;&#x002A;</sup>P&#x003C;0.001 vs. pcDNA3.1; <sup>&#x0023;</sup>P&#x003C;0.05, <sup>&#x0023;&#x0023;</sup>P&#x003C;0.01, <sup>&#x0023;&#x0023;&#x0023;</sup>P&#x003C;0.001 vs. pc-Kcnq1ot1 + agomiR-NC; <sup>&#x0026;&#x0026;&#x0026;</sup>P&#x003C;0.001 vs. pc-Kcnq1ot1 + sh-NC. Kcnq1ot1, long non-coding RNA KCNQ1 opposite strand/antisense transcript 1; miR, microRNA; sh, short hairpin; NC, negative control; Tbx5, T-box transcription factor 5; RUNX, Runt-related transcription factor 2; COL1A1, collagen type I &#x03B1; 1.</p></caption>
<graphic xlink:href="etm-23-03-11117-g05.tif" />
</fig>
</floats-group>
</article>
